P601 Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST study
Remo Panaccione(University of Calgary), Aileen L. Pangan(AbbVie (United States)), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Qian Zhou(Nanjing Foreign Language School), Marc Ferrante(Universitair Ziekenhuis Leuven), Raja Atreya(Friedrich-Alexander-Universität Erlangen-Nürnberg), Fabio Cataldi(Pfizer (United States)), B Huang(AbbVie (United States)), Jeffrey Enejosa(Gilead Sciences (United States)), Ana P. Lacerda(AbbVie (United States)), B E Sands(Icahn School of Medicine at Mount Sinai), María T. Abreu(Icahn School of Medicine at Mount Sinai)
Cited by 7
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k